Primary central nervous system lymphoma: a clinicopathological study of 75 cases

References

• Deckert M, Paulus W. Malignant lymphomas. In: Kleihues P, Cavanee W, editors. World Health Classification of Tumours Pathology and Genetics Tumours of the Nervous System. Lyon: IARC Press, 2007; 188–192.
   Google Scholar
• Haldorsen IS, Krakenes J, Krossnes BK, Mella O, Espeland A. CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989–2003. AJNR Am J Neuroradiol 2009; 30: 744–751.
   PubMed Web of Science ®Google Scholar
• Olson JE, Janney CA, Rao RD, et al The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002; 95: 1504–1510.
   PubMed Web of Science ®Google Scholar
• Kluin PM, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL, editors. World Health Organisation Classification of Tumours Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008; 240–241.
   Google Scholar
• Elder JB, Chen TC. Surgical interventions for primary central nervous system lymphoma. Neurosurg Focus 2006; 21: E13.
   Google Scholar
• Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol 2005; 31: 100–105.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Jones CD, Warnke R, et al Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945–951.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Greiner TC, Patel K, et al Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007; 21: 2332–2343.
   PubMed Web of Science ®Google Scholar
• Seki R, Ohshima K, Fujisaki T, et al Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009; 100: 1842–1847.
   PubMed Web of Science ®Google Scholar
• Braaten KM, Betensky RA, de Leval L, et al BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003; 9: 1063–1069.
   PubMed Web of Science ®Google Scholar
• Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer 2008; 112: 151–156.
   PubMed Web of Science ®Google Scholar
• Lin CH, Kuo KT, Chuang SS, et al Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 2006; 12: 1152–1156.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.
   PubMed Web of Science ®Google Scholar
• Banham AH, Connors JM, Brown PJ, et al Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005; 11: 1065–1072.
   PubMed Web of Science ®Google Scholar
• Sagaert X, de Paepe P, Libbrecht L, et al Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 2490–2497.
   PubMed Web of Science ®Google Scholar
• Schwindt H, Akasaka T, Zuhlke-Jenisch R, et al Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol 2006; 65: 776–782.
   Google Scholar
• Montesinos-Rongen M, Zuhlke-Jenisch R, Gesk S, et al Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol 2002; 61: 926–933.
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Siebert R, Deckert M. Primary lymphoma of the central nervous system: just DLBCL or not? Blood 2009; 113: 7–10.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Spier CM, Miller TP, Slymen DJ, Rybski JA, Grogan TM. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol 1990; 3: 361–367.
   PubMed Web of Science ®Google Scholar
• Xu Y, Kroft SH, McKenna RW, Aquino DB. Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br J Haematol 2001; 112: 945–949.
   PubMed Web of Science ®Google Scholar
• Riemersma SA, Oudejans JJ, Vonk MJ, et al High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J Pathol 2005; 206: 328–336.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, editors. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008.
   Google Scholar
• Chott A, Haedicke W, Mosberger I, et al Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 1998; 153: 1483–1490.
   PubMed Web of Science ®Google Scholar
• Streubel B, Lamprecht A, Dierlamm J, et al T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003; 101: 2335–2339.
   PubMed Web of Science ®Google Scholar
• Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005; 19: 652–658.
   PubMed Web of Science ®Google Scholar
• Shenkier TN, Blay JY, O'Neill BP, et al Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005; 23: 2233–2239.
   PubMed Web of Science ®Google Scholar
• Camilleri-Broet S, Criniere E, Broet P, et al A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006; 107: 190–196.
   PubMed Web of Science ®Google Scholar
• Bhagavathi S, Sharathkumar A, Hunter S, et al Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas. Clin Neuropathol 2008; 27: 13–20.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
   PubMed Web of Science ®Google Scholar
• Chang CC, McClintock S, Cleveland RP, et al Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464–470.
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Brunn A, Bentink S, et al Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 2008; 22: 400–405.
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Schmitz R, Courts C, et al Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. Am J Surg Pathol 2005; 166: 1773–1779.
   Google Scholar
• Hu H, Wang B, Borde M, et al Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol 2006; 7: 819–826.
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002; 2: 920–932.
   PubMed Web of Science ®Google Scholar
• Courts C, Brunn A, Montesinos-Rongen M, et al Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma. J Neuropathol Exp Neurol 2009; 68: 972–976.
   PubMed Web of Science ®Google Scholar
• Goatly A, Bacon CM, Nakamura S, et al FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. Mod Pathol 2008; 21: 902–911.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003; 101: 2914–2923.
   PubMed Web of Science ®Google Scholar
• Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci USA 1996; 93: 6947–6952.
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, et al Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications–a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25: 805–812.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS, et al Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24: 5711–5715.
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Ferlay C, Sebban C, et al Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2010; 21: 842–850.
   PubMed Web of Science ®Google Scholar